Correlation Engine 2.0
Clear Search sequence regions


  • autoantibodies (5)
  • CASPR2 (1)
  • diagnosis (1)
  • GABAA (1)
  • help (1)
  • humans (1)
  • LGI1 (1)
  • NMDA (1)
  • pathogenesis (1)
  • patients (5)
  • receptors (1)
  • seizures (6)
  • Sizes of these terms reflect their relevance to your search.

    Seizures are a common feature of autoimmune encephalitis and are especially prevalent in patients with the commonest autoantibodies, against LGI1, CASPR2 and the NMDA, GABAB, and GABAA receptors. In this chapter, we discuss the classification, clinical, investigation, and treatment aspects of patients with these, and other autoantibody-mediated and -associated, illnesses. We highlight distinctive and common seizure semiologies which, often alongside other features we outline, can help the clinical diagnosis of an autoantibody-associated syndrome. Next, we classify these syndromes by either focusing on whether they represent underlying causative autoantibodies or T-cell-mediated syndromes and on the distinction between acute symptomatic seizures and a more enduring tendency to autoimmune-associated epilepsy, a practical and valuable distinction for both patients and clinicians which relates to the pathogenesis. We emphasize the more effective immunotherapy response in patients with causative autoantibodies, and discuss the emerging evidence for various first-, second-, and third-line immunotherapies. Finally, we highlight available clinical rating scales which can guide autoantibody testing and immunotherapy in patients with seizures of unknown etiology. Throughout, we relate the clinical and therapeutic observations to the immunobiology and neuroscience which drive these seizures. Copyright © 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

    Citation

    Barbara Wagner, Sarosh Irani. Autoimmune and paraneoplastic seizures. Handbook of clinical neurology. 2024;200:151-172

    Expand section icon Mesh Tags

    Expand section icon Substances


    PMID: 38494275

    View Full Text